Effect of variations in treatment regimen and liver cirrhosis on exposure to benzodiazepines during treatment of alcohol withdrawal syndrome

Pavel Gershokovich, Kishor M Wasan, Charles Ribeyre, Fady Ibrahim, John H McNeill

Article Type

Case Report

Published

Benzodiazepines (BDZ) are the drugs of choice to prevent the symptoms of alcohol withdrawal syndrome (AWS). Differences in treatment regimens, the choice of BDZ, as well as the presence of liver cirrhosis can substantially alter the exposure of patients to drugs used for AWS treatment so patients should be carefully monitored.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.